WHY US

Business Wire India is the only Indian news distribution platform to partner with ANI, PTI, IANS, and UNI Testimonials - Whenever we have something important to tell, Business Wire India is often our first point of call, Rajnish Wahi, Senior VP, Corporate Affairs & Communication, Snapdeal. I define Business Wire India as a facilitator for the communications industry, Sudeshna Das, Executive Director, ComConnect. Business Wire India is very good in terms of credible and authentic news distribution to media. It adds authenticity to all content, Arneeta Vasudeva, Vice President, Ogilvy. Business Wire India is the only Indian news distribution platform to partner with ANI, PTI, IANS, and UNI The BW India team is very professional and prompt, we have been working seamlessly with BW for many years now, Prathibha Nair, Assistant Manager - Corporate Communications, Wipro Limited. Businesswire helps us in securing coverage on prominent media outlets across US, Europe and India and the detailed tracking reports allow us to monitor our press release. All members of the servicing team are cooperative and efficient and they truly augment our outreach efforts, Aniruddha Basu, PR & Corporate Communications, L&T Technology Services

(BW)(MA-BRUKER/PROTEOGENIX)(BRKR)

ProteoGenix and Bruker Daltonics Announce Strategic Collaboration for Protein Biomarker Discovery and Screening

  • Wednesday, September 29, 2004 4:46PM IST (11:16AM GMT)
 
Billerica, Mass., Ore., Portland, United States: ProteoGenix Inc., a company with broad expertise in genomics and proteomics applied to biomarker discovery, has selected Bruker Daltonics Inc. as a strategic partner for the development of high-throughput protein biomarker discovery and mass spectrometry based multi-analyte assay platforms. One of ProteoGenix' recent successes was the discovery of biomarkers for intra-amniotic infection, published in the Journal of the American Medical Association. ProteoGenix intends to develop these biomarkers into a screening test to identify women at risk for premature birth from the infection. Development of such a non-invasive test may allow treatment early enough to prevent premature birth and has the potential to prevent up to an estimated 175,000 premature births that occur annually in the U.S. due to intra-amniotic infection. Under their collaboration, the companies will collaborate to implement the ProteoGenix protein biomarker discovery methods on the Bruker Daltonics autoflex(TM) II TOF/TOF instrument. The teams plan to increase the speed, efficiency and throughput of the protein biomarker discovery methods by employing Bruker Daltonics' magnetic bead based ClinProt(TM) platform for automatic processing of serum samples, as well as samples of other body fluids. Other aspects of the collaborative effort will be the use of ClinProTools(TM) comprehensive analysis, visualization and statistical model building software for biomarker discovery, and ProteinScape(TM) software to manage the data processing and archiving from the protein biomarker discovery workflow. Srinivasa Nagalla, M.D., Chief Scientific Officer and acting COO of Proteogenix, commented: "We were delighted to find a partner that can provide a complete solution for protein biomarker discovery and identification, including high performance MALDI TOF/TOF mass spectrometers, together with robotics for automation and high throughput, and the software tools required for data analysis and workflow management. We look forward to working with Bruker Daltonics to implement our methods on their instrumentation." Dr. Gary Kruppa, Vice President of Bruker Daltonics, stated: "We are very pleased that ProteoGenix, a high profile and successful protein biomarker discovery company, has chosen us as their strategic partner. Such customers validate our approach to developing a complete solution to biomarker discovery and identification. We look forward to a fruitful collaboration with ProteoGenix that will assist us in the further development of our biomarker discovery solutions." ABOUT BRUKER BIOSCIENCES CORPORATION (NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on x-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com ABOUT PROTEOGENIX CORPORATION ProteoGenix Inc., headquartered in Portland, Oregon, is a privately held company. ProteoGenix is pioneering the identification of biomarkers and potential therapeutic targets using proprietary genomic and proteomic approaches in the area of Maternal and Fetal Medicine. The major focus is on identification of biomarkers for detection of premature labor and birth defects. ProteoGenix is developing multi-analyte based screening and diagnostic tests for pregnancy-associated conditions. For more information, please visit www.proteogenix.com CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.


Submit your press release

Business Wire

Business Wire
Copyright © 2019 Business Wire India. All Rights Reserved.